Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 12 Carcinoma, Merkel Cell 8 Urinary Bladder Neoplasms 7 Pancreatic Neoplasms 6 Neoplasm Metastasis 6 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Ovarian Neoplasms 4 Neoplasms 4 Stomach Neoplasms 3 Prostatic Neoplasms 3 Melanoma 3 Leukemia, Myeloid, Acute 3 Colorectal Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Sarcoma 2 Head and Neck Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Squamous Cell 2 Carcinoma, Ovarian Epithelial 2 Carcinoma 2 Uterine Cervical Neoplasms 1 Ureteral Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Recurrence 1 Ovarian Diseases 1 Non-Muscle Invasive Bladder Neoplasms 1 Neuroendocrine Tumors 1

Interventions

atezolizumab 3 Etoposide 2 Cisplatin 2 veliparib 1 tivozanib 1 surufatinib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 durvalumab 1 berzosertib 1 avelumab 1 Topotecan 1 Podophyllotoxin 1 Platinum 1 Paclitaxel 1 Nivolumab 1 Ipilimumab 1 Everolimus 1 EC regimen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Neuroendocrine × avelumab × Clear all

NCT03278405 2020-03-18

NET-001

Sunnybrook Health Sciences Centre

Phase 1/2 Completed

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡